Benzinga

Benzinga

Benzinga

mardi, août 25

BridgeBio Pharma Inc

BBIONASDAQ
Trade with Public
Trade with Public
$81.07
-0.43-0.53%
À la clôture: Aug 21, 5:00 PM EST
$81.07
-0.43-0.53%
Pré-ouverture: 4:33 AM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerRapport sur les stocks

BridgeBio Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for BridgeBio Pharma (BBIO).

Price Target Range — 9 Quarters

Analyst Consensus — 25 Analysts

23Buy
2Hold
Consensus RatingBuy# Analysts25Avg. Consensus PT$91Upside to Avg. PT+12.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 12, 2026Truist SecuritiesDanielle BrillPT RaiseBuy$102→$107
Aug 12, 2026Canaccord GenuityWhitney IjemPT RaiseBuy$104→$106
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107

Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $102 to $107.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106

Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $104 to $106.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $111

JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $100 to $111.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $104

B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $101 to $104.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on BridgeBio Pharma, Raises Price Target to $110

TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $95 to $110.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $97

Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $98 to $97.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved